A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Pharmacokinetics after 2-weeks Administration of CPL207280 (GPR40 agonist) in Subjects With Type 2 Diabetes (T2D)
Log in to eCRF
E-mail
E-mail
Forgot your password?
BioStat is responsible for data management and statistical analysis.
BioStat CBR
eCRF.biz